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Introduction: Thrombocytopenia is one of the numerous complications of malaria infection, which could be lethal 
if not diagnosed and managed on time. Our study aims to determine the occurrence of thrombocytopenia in 
patients hospitalized with malaria. 
Material and Methods: A retrospective cross-sectional study was conducted between January 2016 till December 
2019. Data was collected from the patient’s record registers. A total of 201 cases were included in this study. Data 
was collected, entered, and analyzed in IBM SPSS 23 software package. 
Results: Out of the total 201 cases, 108 (53.7%) were males and 93 (46.3%) were females. 189 (94%) cases were 
suffering from P. vivax, 10 (5%) were suffering from P. falciparum, and cases suffering from both were only 2 (1%). 
Thrombocytopenia was present in 183 (91.04%) cases (95% confidence interval 2.13-2.37). 91.53% (n=173) of cases 
diagnosed with P. vivax had thrombocytopenia while 90% (n=9) cases diagnosed with P. falciparum had 
thrombocytopenia. 
Conclusion: We conclude from this study that, thrombocytopenia occurs in all species of malaria and is not a 
distinguishing feature between the principal types of malaria. With prompt identification and management, 
platelets count reverts back to normal. 
Keywords: Malaria, Thrombocytopenia, Plasmodium vivax, Plasmodium falciparum. 
 




Malaria is a devastating disease caused by Plasmodium, 
a protozoan parasite.1 Four different species of 
Plasmodium i-e P. falciparum, P. malariae, P. ovale, 
and P. vivax are the main contributors of human 
malaria infection. It is prevalent around the world, 
notably in tropical and subtropical areas.2 Plasmodium 
vivax is the most geographically prevalent species out 
of them. Around 40% of the population of the world is 
affected by it.3,4 
Malaria infection is a threat to half of the global 
population.5 In 2017, 219 million clinical cases and 
435,000 deaths due to malaria infection had been 
reported worldwide.2 Contribution of south-east Asia 
is underestimated, contributing >40% burden of global 
infection.5 In 2015, the estimated global mortality rate 
was 429,000 due to malaria. Major contributors, which 
is more than 36% of malaria deaths were countries in 
sub-Saharan Africa, with the Democratic Republic of 
the Congo and Nigeria together. Four countries 
(Ethiopia, India, Indonesia, and Pakistan) accounted 
for 81% of estimated deaths due to PV malaria.6 
Pakistan has been grouped with Sudan, Yemen, 
Somalia, and Afghanistan under one of the highest 
malaria burden-sharing countries with an estimation 
of 1 million cases of malaria annually.6 Regarding the 
high infectivity rate of malaria in Pakistan, the 
Directorate of Malaria Control has reported that One 
individual per thousand is infected with malaria.7 
There is a high variation in the prevalence of the 
Plasmodium parasite among different regions of 
Pakistan. Malaria infection is principally attributed to 
P. vivax, but P. falciparum but mixed infections are 
also prevalent.8 Malaria is primarily found in Federally 
Administered Tribal Areas, followed by Baluchistan 
and Khyber Pakhtunkhwa.9 
Clinically malaria has no definitive diagnostic features 
as it imitates many diseases clinically. It mainly affects 
RBCs (Red blood cells) and causing a hematological 
abnormality of anemia, but thrombocytopenia is also a 
well-known complication in almost every part of the 
world. It has been documented with mono-infection i-
e P. falciparum and P. vivax and also with combined 
infection of both.10,11 
Several observational studies have established the 
association of thrombocytopenia to malaria, but to this 
day, the cause of thrombocytopenia is not adequately 
understood. There is no exact mechanism known yet 
for malaria induced thrombocytopenia but seems to 
occur due to peripheral destruction, splenic 
sequestration, excessive consumption in the process of 
DIC (disseminated intravascular coagulation) immune 
destruction, alteration in the bone marrow and 
binding of platelets to infected red blood cells causing 
pseudo-thrombocytopenia and oxidative stress is also 
a contributing factor.12 According to some recent 
evidence, besides the principal function of clotting, 
platelets are suggested to contribute to the killing of 
malarial parasites and clearing the infection.13 
In various studies conducted about malaria induced 
thrombocytopenia, there was an incidence of 48-57% 
of thrombocytopenia in the malaria-affected patient.11 
In almost every case, thrombocytopenia is not linked 
to bleeding and requires no treatment. The platelet 
counts rapidly revert to normal after the successful 
treatment of the malarial episode, although 
thrombocytopenia associated with bleeding is one of 
the clinical manifestations of severe malaria and is one 
of the major causes of mortality in older infants and 
children(3). It has been reported that a 9-fold increase 
in the risk of mortality from P. vivax in children with 
severe anemia and severe thrombocytopenia, as 
compared to those without anemia or 
thrombocytopenia.13 Studies have shown the 
association of low platelet count with an increase in 
mortality in patients with P. Falciparum and P. vivax 
infections.15,16 A recent increase in a number of studies 
is seen, which have addressed the frequency of 
thrombocytopenia in P. vivax infection. 
Understanding the mechanism, occurrence, and role of 
thrombocytopenia in malaria may improve clinical 
practice guidelines and recuperate the risk of mortality 
in severe cases. 
 
Materials and Methods 
 
This research was conducted as a retrospective cross-
sectional study. Data were collected from the patient’s 
record register from January 2016 till December 2019. 
Data was recorded on proforma specially designed for 
this study. A total of 201 cases were included in this 
study. The research reported here was conducted in 
Bilal Medical Trust Hospital, a private hospital in 
District Buner. Buner is a district in the Malakand 
division of Khyber Pakhtunkhwa province in Pakistan. 
This hospital is a trust hospital and provides 
healthcare to different social classes of people all over 
Buner. 
The inclusion criteria for this study were all the 
patients presenting with high-grade fever, and a 
diagnosis of malaria was made with thin and thick 
blood smear films. All patients in this endemic area 
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with fever are suspected to have malaria due to P. 
vivax, given this is the unique species in this zone. 
Patients with malaria treated outside the hospital, no 
platelet count available before the initiation of 
treatment, known HIV positive status, known 
thrombocytopenia/platelet disorders, mean 
corpuscular volume (MCV) < 75 (suggesting iron 
deficiency anemia), known chronic renal failure or 
clinical diagnosis of malaria without slide positivity 
were excluded from the study. 
Baseline platelet levels were done before initiation of 
treatment and then repeated on the third day for every 
patient after the initiation of treatment. Platelets were 
measured using Swelab Alfa Plus Systems. Mild 
thrombocytopenia was defined as platelet count 
100,000 to 150,000/microL, moderate as 50,000 to 
99,000/microL and severe as <50,000/microL.17 
Ethical approval was obtained from the Ethical Review 
Board of Prime Foundation, Peshawar Medical 
College, Warsak Road Peshawar. The data was 
entered and analyzed in IBM SPSS software package 
version 23. Descriptive statistics were used to analyze 
gender, malaria parasites, and platelet counts.  A 
paired sample t-test was used to analyze platelet 





Out of the total 201 cases which were included in this 
study, 108 (53.7%) were males, and 93 (46.3%) were 
females. 189 (94%) cases were suffering from 
Plasmodium vivax, 10 (5%) were suffering from 
Plasmodium falciparum, and cases infected with both 
P. vivax, and P. falciparum were only 2 (1%). 
Thrombocytopenia was present in 183 (91.04%) cases 
(95% confidence interval 2.13-2.37). Among the 183 
cases with thrombocytopenia, 96 (52.45%) were males, 
and 84 (45.9%) were females. P. vivax was as likely 
associated with thrombocytopenia as P. falciparum 
(Table 1). 91.53% (n=173) of cases diagnosed with 
vivax had thrombocytopenia while 90% (n=9) cases 
diagnosed with P. falciparum had thrombocytopenia. 
Platelet counts on the third day started to improve, as 
seen in Table 2. The p-value of platelet count before 
and after treatment was <0.05, as seen in Table 3. 
Similarly, the p-value of platelet count before 
treatment and 3rd day of treatment was highly 
significant (<0.005) and the p-value of platelet count 
between 3rd day and after treatment was also <0.005. 
 
 
Table 1: Thrombocytopenia with Malarial Parasites on Day 0 
 <50,000 50,000-99,000 100,000-150,000 >150,000 Total 
P. vivax 39 (20.6%) 82 (43.4%) 52 (27.5%) 16 (8.5%) 189 (100%) 
P. falciparum 3 (30%) 3 (30%) 3 (30%) 1 (10%) 10 (100%) 
Both 0 (0%) 0 (0%) 1 (50%) 1 (50%) 2 (100%) 
Total 42 (20.9%) 85 (42.3%) 56 (27.9%) 18 (9%) 201 (100%) 
 
Table 2: Thrombocytopenia with Malarial parasites on Day 3 
 <50,000 50,000-99,000 100,000-150,000 >150,000 Total 
P. vivax 9 (4.8%) 97 (51.3%) 55 (29.1%) 28 (14.8%) 189 (100%) 
P. falciparum 0 (0%) 5 (50%) 3 (30%) 2 (20%) 10 (100%) 
Both 0 (0%) 0 (0%) 1 (50%) 1 (50%) 2 (100%) 
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Table 3: Comparison between Platelet counts before, during, and after treatment 
 Mean N Standard Deviation P-Value 
Platelets before 
treatment 
88169.1542 201 43323.9108 <0.05 
Platelets after 15 days 
at follow-up 
226512.935 201 42561.9270 
Platelets before 
treatment 
88169.1542 201 43323.9108 <0.001 
Platelets on 3rd day of 
treatment 
15753.731 201 43249.7433 
Platelets on 3rd day of 
treatment 
105753.731 201 43249.7433 <0.001 
Platelets after 15 days 
at follow-up 




In this study males (n=108, 53.7%) were infected more 
than females (n=93, 46.3%). Similar results were also 
found in a study conducted in the Larkana district of 
Sindh, which also found that males were infected more 
than females(18). Another study conducted in district 
Buner also found out that males had a high incidence 
rate than females, which goes in favor of our study. 
Males had a percentage of 68.9%, and females had a 
percentage of 31.09%.19 
According to a malariometric population survey, P. 
falciparum had a high prevalence than P. vivax in the 
province of Khyber Pakhtunkhwa at 10% and 8%, 
respectively.8 Our results demonstrated that the 
infection with P. vivax was more than P. falciparum 
(94% vs. 5%, respectively).  1% percent of the total 
individuals had mixed infection with both P. vivax 
and P. falciparum. According to Khan et al.20, out of 
the total individuals that were investigated for 
malaria, 17.35% were found to be positive for malarial 
parasite; P. vivax was 91.53%, 7.47% were infected 
with P. falciparum while patients that were infected 
with both the species were <1%. The results of this 
study are very close to our study. Similar results were 
also achieved by another study that was conducted in 
the Larkana district of Sindh, and they also 
determined that P. vivax infection was more than P. 
falciparum.18 
Out of the total 201 cases, thrombocytopenia was 
present in 91.04% of cases (n=183). Among these, 
males (n=96, 52.45%) had a high incidence of 
thrombocytopenia than females (n=84, 45.9%). 
Assorted contraptions are hypothesized for 
thrombocytopenia in malaria, such as platelet 
aggregation, oxidative stress, splenic sequestration, 
and antibody-mediated destruction(12). Contrary to a 
widespread belief, P. vivax gives rise to 
thrombocytopenia21, as was seen in this study. 91.53% 
of patients suffering from P. vivax had 
thrombocytopenia and 90% in patients with P. 
falciparum. Thrombocytopenia was detected in both 
the patient groups infected with either P. vivax or P. 
falciparum, as well as in patients having both 
infections. Similar findings were noted in a study 
conducted by Erhart et al. from western Thailand.22 
Another study that was conducted in India on the 
relationship of thrombocytopenia with malarial 
species also yielded similar results. They described 
thrombocytopenia in both P. vivax and P. falciparum 
but severe thrombocytopenia was more consistent 
with the latter.23 Contrary to this, our study yielded 
results that showed that patients infected with P. vivax 
had severe thrombocytopenia than patients infected 
with P. falciparum. 
In this study, patients with thrombocytopenia on day 0 
(before initiation of treatment) were 182 (90.54%) of 
the total 201 cases. Patients diagnosed with P. vivax 
and thrombocytopenia were 173 (91.53%) out of the 
total diagnosed with P. vivax (n=183) and those 
diagnosed with P. falciparum and thrombocytopenia 
were 9 (90%) out of the total diagnosed with P. 
falciparum (n=10). Patients having severe 
thrombocytopenia were 42 (20.9%) out of the total 201 
cases. Those having moderate thrombocytopenia were 
85 (42.3%), while patients having moderate 
thrombocytopenia were 56 (27.9%) out of the total 201 
cases diagnosed with malaria. The results of our study 
are parallel to few other studies, which also concluded 
that patients suffering from malaria showed some 
extent of thrombocytopenia, and thrombocytopenia is 
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more prominent in the initial period of disease before 
the initiation of treatment.24,25 
Platelet counts were repeated on 3rd day after initiation 
of treatment. Improvement was seen in the platelet 
counts of patients. Only 4.6% (n=9) patients had severe 
thrombocytopenia in comparison to day 0.  Similarly, 
50.7% (n=102) patients had moderate 
thrombocytopenia while 29.4% (n=59) patients had 
mild thrombocytopenia. Similar results were achieved 
by other studies in this regard as well; they discovered 
that with the initiation of treatment, the meantime for 
the disappearance of malarial parasite from the blood 




We conclude from this study that thrombocytopenia 
occurs in all species of malaria and is not a 
distinguishing attribute between the different types of 
malaria. With prompt identification and management, 
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